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Objectives. This study was designed to identify potential pre-
dictors of vascular access site (VAS) complications in the large-
scale Integrilin to Minimize Platelet Aggregation and Coronary
Thrombosis (IMPACT) II trial, which studied angioplasty with
versus without a new glycoprotein (GP) IIb/IIIa receptor inhibitor
(eptifibatide).
Background. GP IIb/IIIa receptor inhibition during coronary
interventions has been associated with excess VAS complications.
If other predictors of VAS complications could be identified, they
might be manipulated to reduce complications.
Methods. A total of 4,010 patients undergoing percutaneous
transluminal coronary revascularization (PTCR) were random-
ized into one of three bolus/20- to 24-h infusion arms: placebo
bolus/placebo infusion; 135-mg/kg body weight eptifibatide bolus/
0.5-mg/kg per min eptifibatide infusion; or 135-mg/kg eptifibatide
bolus/0.75-mg/kg per min eptifibatide infusion. Heparin during
the procedure was weight adjusted and stopped 4 h before sheaths
were removed. Logistic regression modeling was used to identify
independent predictors of VAS complications.
Results. VAS complications were more common in patients
treated with eptifibatide (9.9% vs. 5.9% placebo-treated patients,
p < 0.001). Multivariate analysis identified eptifibatide therapy
(p < 0.0001), advanced age (p 5 0.0001), longer time to sheath
removal (p 5 0.0002), stent placement (with intense post-stent
anticoagulation) (p 5 0.0004), female gender (p 5 0.0006), PTCR
within 24 h of thrombolytic therapy (p 5 0.002), larger heparin
doses during PTCR (p 5 0.009), major coronary dissection (p 5
0.03) and placement of a venous sheath (p 5 0.04) as independent
predictors of VAS complications.
Conclusions. VAS complications may be reduced by early
sheath removal, by avoiding placement of venous sheaths and by
limiting heparin dosing to avoid excessive activated clotting times.
Early sheath removal during inhibition of platelet aggregation by
eptifibatide is feasible.
(J Am Coll Cardiol 1998;31:1518–24)
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Percutaneous transluminal coronary revascularization (PTCR)
involves a fundamental dilemma—the need to prevent throm-
bosis of the target vessel while promoting hemostasis of the
vascular access site (VAS). More robust antithrombotic pro-
tocols, designed to minimize abrupt target vessel closure, are
associated with higher rates of VAS complications (1–4).
Although some devices and drugs may improve short- and
long-term outcomes of PTCR, the increased incidence of
access site complications may limit the overall benefit of the
treatment strategy (2–4).
Patient and procedural characteristics that predict vascular
complications of PTCR have been identified in the era before
glycoprotein (GP) IIb/IIIa platelet receptor inhibition. To
identify predictors of VAS complications in patients undergo-
ing PTCR during GP IIb/IIIa platelet receptor inhibition, we
studied the 3,871 patients who received the study drug in the
Integrilin to Minimize Platelet Aggregation and Coronary
Thrombosis (IMPACT) II trial (5). The size of the IMPACT II
trial, its inclusion of a broad spectrum of patients and its
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multicenter design provided a unique opportunity to study
VAS complications. The present analysis focused on variables
that might affect the incidence of VAS complications in future
patients.
Methods
Study design. The IMPACT II trial was a multicenter
randomized, double-blind efficacy and safety evaluation of
eptifibatide, a cyclic heptapeptide inhibitor of the GP IIb/IIIa
receptor, for reducing the ischemic complications of coronary
angioplasty (5). The study enrolled 4,010 patients scheduled
for PTCR with any Food and Drug Administration-approved
device between November 1993 and November 1994. Inclusion
and exclusion criteria have been published previously (5). The
study protocol was approved by the investigational review
board of each participating institution, and written informed
consent for participation was received from each patient. After
randomization, 139 patients did not receive the study drug
because of changes in clinical status or withdrawal from the
study. This analysis involves the 3,871 patients who received
the study drug in one of three bolus/20- to 24-h infusion arms:
placebo bolus/placebo infusion; 135-mg/kg body weight eptifi-
batide bolus/0.5-mg/kg per min eptifibatide infusion; or 135-
mg/kg eptifibatide bolus/0.75-mg/kg per min eptifibatide infu-
sion. At the operator’s discretion, heparin therapy was
continued 20 to 24 h or discontinued immediately after the
procedure. Access site sheaths were removed after heparin was
discontinued and when activated partial thromboplastin time
(aPTT) measured ,45 seconds or activated clotting time
(ACT) measured ,150 s. The protocol called for hemostasis to
be established with commercially available hemostasis clamps
with pressure applied for at least 30 min. If clinically indicated,
heparin was reinstituted 3 to 4 h after hemostasis with a
standard bolus of 7.5 U/kg and infusion rate as needed to
maintain aPTT at two to three times control values.
Baseline clinical, procedural and postprocedural care char-
acteristics were prospectively recorded using a case report
form designed to assess VAS complications. Investigators
rated VAS bleeding as mild, moderate (requiring transfusion)
or severe (causing hemodynamic compromise and requiring
transfusion or volume replacement) and recorded the inci-
dence of pseudoaneurysms, arteriovenous fistulas and any
access site lesion requiring surgical repair. Length of stay in the
hospital after the procedure was recorded.
Statistical analysis. Statistical analyses were performed to
identify predictors of VAS complications defined as any mod-
erate/severe VAS bleeding or pseudoaneurysm/arteriovenous
fistula/surgical VAS repair.
The 135/0.5- and 135/0.75-dose eptifibatide groups were
pooled for all analyses, because the IMPACT II trial demon-
strated insignificant differences between them in overall effi-
cacy or bleeding complications (5). The eptifibatide and pla-
cebo groups were compared with regard to 35 baseline
characteristics, 27 procedural characteristics and 12 postpro-
cedural care characteristics using chi-square analysis for dis-
crete variables and Wilcoxon rank sum tests for continuous
variables. Each clinical, procedural and postprocedural vari-
able was correlated with the incidence of the combined com-
plication end point. Correlations were evaluated using chi-
square analysis for discrete variables and Wilcoxon rank sum
tests for continuous variables. Multivariable logistic regression
analysis of the univariate predictors was performed to deter-
mine which variables were independently associated with
access site complications. Separate multivariable logistic mod-
els were made, the first using only baseline patient features and
the second using all univariate predictors. A p value , 0.05 was
considered statistically significant. Postprocedural care charac-
teristics were not included in the multivariable analysis because
it was difficult to determine whether they independently con-
tributed to or were dependent on VAS complications.
Results
Moderate to severe VAS bleeding or pseudoaneurysm/
arteriovenous fistula/surgical VAS repair occurred in 8.5% of
all IMPACT II patients. Of these, 7.1% had moderate VAS
bleeding, 0.5% had severe VAS bleeding, and 1.7% had
pseudoaneurysm/arteriovenous fistula/surgical VAS repair.
Access site bleeding accounted for 71% of all moderate to
severe bleeding complications in IMPACT II patients who
received the study drug. Table 1 lists the incidence of each of
these complications in the three treatment groups.
The treatment groups were similar with regard to baseline
patient characteristics. Among procedural variables, eptifi-
batide prolonged median and interquartile ACT values com-
pared with placebo (high dose eptifibatide 366 s [329 to 416],
low dose eptifibatide 362 s [329 to 412] and placebo 349 s [319
to 395]).
There was modest variation in the incidence of any VAS
complications across the 82 sites enrolling patients. The me-
dian incidence (25th, 75th percentile) of any VAS complica-
tions was 5.5% [0, 10.3].
Univariate analysis. Univariate analysis identified 10 base-
line characteristics and 12 procedural variables significantly
associated with the incidence of any VAS complication (Table
Abbreviations and Acronyms
ACT 5 activated clotting time
EPIC 5 Evaluation of c7E3 Fab in Preventing Ischemic
Complications of High Risk Angioplasty
EPILOG 5 Evaluation in PTCA to Improve Long-Term
Outcome with Abciximab Glycoprotein IIb/IIIa
Blockade
GP 5 glycoprotein
IMPACT 5 Integrilin to Minimize Platelet Aggregation and
Coronary Thrombosis
OR 5 odds ratio
PROLOG 5 Precursor to EPILOG Study
PTCR 5 percutaneous transluminal coronary revascularization
VAS 5 vascular access site
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2). The incidence of any VAS complications was higher with
PTCR within 24 h of lytic therapy (25.9% vs. 8.4% in all other
patients, p 5 0.006), eptifibatide therapy (9.9% vs. 5.9% in
placebo-treated patients, p , 0.0001), placement of a venous
sheath (9.3% vs. 6.4% without a venous sheath, p 5 0.004) and
placement of a balloon pump (19.3% vs. 9.3% without balloon
pump, p 5 0.002). Among continuous variables, increased
incidence of VAS complications was associated with increasing
arterial sheath size (p 5 0.05), maximal in-laboratory ACT
(p 5 0.003), total heparin dose (p 5 0.01) and time to sheath
removal (p 5 0.0002). Univariate analysis also identified eight
postprocedural care characteristics significantly associated
with the incidence of any VAS complication (Table 3).
Multivariable analysis. Multivariable analysis using only
baseline patient features identified four features that were
associated with VAS complications: age, eptifibatide therapy,
PTCR within 24 h of lytic therapy and female gender. When
multivariable analysis was performed using all the significant
univariate determinants, nine of them remained significant
independent predictors of risk in multivariable analysis (Table
4). The largest odds ratios were observed for PTCR within 24 h
of lytic therapy (p 5 0.002, odds ratio [OR] 5.2), in-laboratory
stent placement (p 5 0.0004, OR 2.6), eptifibatide therapy
(p , 0.0001, OR 1.9) and presence of major coronary dissec-
tion during PTCR (p 5 0.03, OR 1.7).
The incidence of pseudoaneurysm/arteriovenous fistula/
surgical VAS repair was too low to perform a separate analysis
of predictors. There was no trend toward more frequent
structural complications with eptifibatide.
Length of stay. Length of stay after the procedure was
prolonged in patients with VAS complications. Median length
of stay [25th, 75th percentiles] after PTCR was 3 d [2, 6] for
patients with VAS complications (vs. 2 days [1, 3] for patients
without VAS complications, p 5 0.0001); 6 days [4, 9] for
patients with severe VAS bleeding (vs. 2 days [1, 3] for patients
without severe bleeding, p , 0.0001); 3 days [2, 5] for patients
with moderate or severe bleeding (vs. 2 days [1, 3] for patients
without moderate or severe bleeding, p , 0.0001); and 6 days
[4, 9] for patients with pseudoaneurysm, arteriovenous fistula
or surgical repair (vs. 2 days [1, 3] for patients without these
events, p , 0.0001).
Discussion
Primary findings. The most significant finding of this study is
that several factors under operator control may affect the
incidence of VAS complications of PTCR performed with GP
IIb/IIIa receptor inhibition. Because eptifibatide increased the
risk of VAS complications twofold, and because VAS bleeding
accounted for 71% of all moderate to severe bleeding compli-
cations in the IMPACT II trial, the identification of risk factors
that can be modified to decrease the incidence of VAS
complications is important.
Potentially modifiable predictors of VAS complications in
the present study included PTCR within 24 h of lytic therapy,
higher in-laboratory ACT values and heparin doses, the occur-
rence of PTCR complications treated with more intense
anticoagulation (major coronary dissection, rescue stenting),
venous sheath placement and late sheath removal.
Baseline patient characteristics. Consistent with previous
studies, advanced age (1,6–10) and female gender (6,7,9–11)
predicted VAS complications. Patients with thrombolytic ther-
apy in the 24 h before enrollment had a 25.9% incidence of
VAS complications compared with 8.4% in patients without
thrombolytic therapy in the preceding 24 h (p 5 0.006). No
significant interaction was observed between eptifibatide and
recent thrombolytic therapy, suggesting that the increased risk
of VAS complications after recent lytic therapy occurs with or
without eptifibatide therapy.
Procedural factors. The finding in the present study that
total heparin dosing is associated with a higher risk of VAS
complications is consistent with other reports. In the Evalua-
tion of c7E3 Fab in Preventing Ischemic Complications of
High Risk Angioplasty trial (EPIC), with the GP IIb/IIIa
receptor blocker abciximab, all patients received heparin; the
maximal in-laboratory ACT was associated with an excess risk
of major/minor VAS bleeding (11). The Precursor to EPILOG
Study (PROLOG) of low dose (median 5,800 U) versus high
dose (median 8,700 U) weight-adjusted heparin during angio-
plasty with abciximab produced lower ACTs and a two- to
threefold reduction in VAS bleeding complications (12). In the
Evaluation in PTCA to Improve Long-Term Outcome with
Abciximab Glycoprotein IIb/IIIa Blockade (EPILOG) trial,
major/minor VAS complications of angioplasty occurred in
2.8% of patients treated with heparin versus 4.0% in patients
with abciximab/low dose heparin versus 7.6% in patients with
abciximab/high dose heparin (13). Thus, four studies of angio-
plasty with GP IIb/IIIa receptor inhibition suggest that higher
doses of heparin producing higher ACTs are associated with
excess VAS complications. Data from the PROLOG and
EPILOG trials demonstrate no excess in ischemic complica-
tions with lower heparin dosing, and data from IMPACT II (5)
suggest this may be true for eptifibatide as well. Recommended
Table 1. Vascular Access Site Complications by Treatment Received
in 3,871 Study Patients
Eptifibatide
Placebo*
(n 5 1,285)
135/0.75 Dose
(n 5 1,286)
135/0.5 Dose
(n 5 1,300)
Investigator-rated moderate 9.5% 7.1% 4.9%
access site bleed p 5 0.001 p 5 0.02
Investigator-rated severe access 0.5% 0.7% 0.5%
site bleed p 5 1.0 p 5 0.45
Investigator-rated moderate or 10.0% 7.8% 5.4%
severe access site bleed p 5 0.001 p 5 0.01
Pseudoaneurysm, AVF or 1.5% 2.2% 1.3%
surgical repair p 5 0.74 p 5 0.08
Any investigator-rated moderate 10.9% 8.9% 5.9%
or severe bleed,
pseudoaneurysm, AVF or
surgical repair
p 5 0.001 p 5 0.003
*p value versus placebo. AVF 5 arteriovenous fistula.
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ACT thresholds for angioplasty with abciximab have been
reduced, and it is possible that similar recommendations will
be made for eptifibatide in the future. In the meantime, it
would seem prudent to avoid raising the ACT much above
300 s when angioplasty is performed with eptifibatide.
Venous sheaths have been used since the early days of
angioplasty to allow temporary transvenous pacemaker place-
ment, infusion of fluid or withdrawal of blood for laboratory
testing. However, temporary pacing is rarely necessary (14), and
peripheral venous access sites can be used for fluid administration
and blood withdrawal. Some interventionists currently use venous
sheaths only as needed. In the present study, 74% of patients
underwent venous sheath placement, with a 35% increase in the
incidence of vascular access complications. Although this may
reflect a population at higher risk of complications, it is also
possible that additional needle thrusts aimed at the vein may
penetrate the artery or that oozing from venous puncture sites
may be a significant source of blood loss. Until further data are
available to confirm this observation, it is reasonable to avoid
routine venous sheath placement in patients with good peripheral
access who are unlikely to need temporary pacing.
Other procedural factors associated with VAS complica-
tions in the present study included placement of a coronary
stent to rescue an inadequate angioplasty result, and major
coronary dissection during angioplasty. The IMPACT II trial
was performed in the era of intense post-stent anticoagulation
including post-stent heparin and warfarin, which produced
excessive VAS complications in previous studies (3,4). Major
Table 2. Univariable Predictors of Vascular Access Site Complications: Baseline Characteristics and
Procedural Characteristics
Characteristic
No VAS
Complication
VAS
Complication p Value
Baseline
Female 858 (24%) 113 (34%) , 0.0001
Male 2,677 (76%) 217 (66%)
Age (yr) 60 (52, 68) 63 (54, 72) 0.0001
Smoking history 2,329 (66%) 189 (57%) 0.001
Nonsmoker 1,189 (34%) 141 (43%)
Height (cm) 173 (167, 180) 172 (165, 178) 0.004
Hemoglobin (g/dl)* 14.0 (13.0, 15.0) 13.9 (12.7, 14.7) 0.004
Lytics in prev 24 h 20 (,1%) 7 (2%) 0.006
No lytics 3,515 (.99%) 323 (98%)
SBP (mm Hg) 130 (118, 144) 133 (120, 149) 0.01
Hematocrit (%) 41 (38, 44) 41 (37, 43) 0.02
Weight (kg) 84 (75, 95) 81 (72, 95) 0.03
HTN 1,900 (54%) 196 (59%) 0.05
No HTN 1,629 (46%) 134 (41%)
Procedural
Eptifibatide 2,328 (66%) 255 (77%) , 0.0001
No eptifibatide 1,207 (34%) 75 (23%)
Stent for any indication 119 (3%) 35 (11%) , 0.0001
No stent 3,416 (97%) 285 (89%)
Major dissection 204 (6%) 47 (14%) , 0.0001
No major dissection 3,267 (94%) 279 (86%)
Length of procedure (min) 29 (16, 49) 36 (21, 59) 0.0001
Time to sheath removal (h) 16 (7, 23) 19 (8, 24) 0.0002
Stent for abrupt closure 23 (,1%) 9 (3%) 0.001
No stent for abrupt closure 3,512 (.99%) 321 (97%)
IABP used 67 (2%) 16 (5%) 0.002
No IABP 3,467 (98%) 314 (95%)
Max in-lab ACT (s) 358 (324, 406) 372 (329, 423) 0.003
Venous sheath placed 2,578 (73%) 263 (80%) 0.004
No venous sheath 952 (27%) 65 (20%)
Total heparin dose (U) 12,000 12,721 0.01
(9,853, 15,500) (10,000, 16,706)
Arterial sheath size (F)* 8 (8, 9) 8 (8, 9) 0.05
Vessel treated (RCA) 1,277 (36%) 137 (42%) 0.05
Vessel treated (other than RCA) 2,258 (64%) 193 (58%)
*Tests of significance are based on the entire distribution of the two groups and may not be reflected in the median
(25th, 75th percentiles). Data presented are number (%) of patients or (for continuous variables) median (25th, 75th
percentiles). ACT 5 activated clotting time; HTN 5 hypertension; IABP 5 intraaortic balloon pump; lab 5 laboratory;
max 5 maximal; prev 5 previous; RCA 5 right coronary artery; SBP 5 systolic blood pressure; VAS 5 vascular access
site.
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dissection during the IMPACT II trial was treated with post-
procedural heparin, which increases VAS bleeding (15–17).
Current practice avoids such intense anticoagulation: Major
coronary dissections are now routinely stented, and stents for
angioplasty failures are routinely treated only with aspirin and
ticlopidine.
Arterial sheath size was a univariate predictor that lost
significance in the multivariable model. This weak associa-
tion of vascular sheath size with VAS complications in the
present study reflects discordant results of previous studies.
Larger arterial sheath size has been associated with access
site complications in several (7–9,18) but not all studies
(1,19 –22).
Postprocedural factors. Some postprocedural treatment
variables associated with VAS complications probably contrib-
uted to those complications. Postprocedural heparin adminis-
tration increases appeared to increase VAS bleeding in this
and other (15–17) studies and is probably of no benefit because
it does not prevent early occlusion (17). Longer duration of
sheath insertion increases VAS complications, probably by
increasing oozing around the sheath, sheath kinking or sheath
dislodgment. Previous reports also have identified prolonged
sheath insertion as a predictor of vascular complications (1,18)
and have demonstrated the safety of early sheath removal
during infusion of the GP IIb/IIIa receptor blocker abciximab
Table 3. Univariable Predictors of Vascular Access Site Complications: Postprocedural Characteristics
No VAS
Complication
VAS
Complication p Value*
Postprocedural heparin 2,472 (70%) 52 (16%) , 0.0001
None 1,061 (30%) 278 (84%)
Bed rest after sheath removal (h) 14 (8, 19) 18 (10, 28) 0.0001
Nadir platelet count 194 (162, 232) 175 (143, 218) 0.0001
Time to sheath removal (h) 16 (7, 23) 19 (8, 24) 0.0002
VAS compression†
Femostop 562 (16%) 93 (29%) , 0.0001
Other 358 (10%) 57 (18%) , 0.0001
Manual 2,104 (61%) 223 (70%) 0.001
C-clamp 983 (29%) 76 (24%) 0.07
Sandbag 1,446 (42%) 149 (47%) 0.1
Sheath removed by
MD 789 (23%) 95 (29%) 0.01
Technician 568 (16%) 36 (11%) 0.01
Physician assistant 109 (3%) 3 (,1%) 0.02
LPN 58 (2%) 4 (1%) 0.53
RN 1,925 (55%) 185 (56%) 0.64
Patient positioning*
Complete bed rest 2,050 (59%) 201 (61%) 0.4
Elevated head of bed 1,764 (51%) 163 (50%) 0.73
Log rolling permitted 986 (28%) 100 (31%) 0.41
Leg restrained 1,267 (37%) 138 (43%) 0.04
VAS hematoma before sheath pull 527 (57%) 164 (69%) 0.001
Oozing before sheath pull 1,555 (91%) 245 (91%) 0.69
Dressing
Pressure dressing 2,577 (74%) 241 (74%)
Band-Aid 373 (11%) 28 (9%) 0.06
Op site 230 (7%) 16 (5%)
Other 290 (8%) 40 (12%)
*Patients treated versus those not treated with specified method. †Many patients treated with more than one method.
Data presented are number (%) of patients or (for continuous variables) median (25th, 75th percentiles). LPN 5 licensed
practical nurse; MD 5 physician; Op 5 operative; RN 5 registered nurse; VAS 5 vascular access site.
Table 4. Multivariable Analysis With Baseline Patient Features and
Procedural Characteristics
Characteristic p Value
OR
(95% CI per
increment in
variable)
Eptifibatide therapy (vs. no eptifibatide) , 0.0001 1.90 (1.45–2.53)
Age (per each 10-yr increase) 0.0001 1.26 (1.13–1.41)
Time to sheath pull (per 1-h increase) 0.0002 1.02 (1.01–1.03)
In-lab stent placement (vs. no stent) 0.0004 2.62 (1.56–4.35)
Female (vs. male) 0.0006 1.59 (1.22–2.06)
PTCR within 24 h of lytic therapy (vs.
PTCR not within 24 h of lytic therapy)
0.002 5.17 (1.93–12.48)
Total heparin dose during procedure (per
each additional 1,000 U)
0.009 1.04 (1.01–1.08)
Major dissection (vs. no major dissection) 0.03 1.67 (1.05–2.58)
Venous sheath (vs. no venous sheath) 0.04 1.35 (1.01–1.82)
CI 5 confidence interval; lab 5 laboratory; OR 5 odds ratio; PTCR 5
percutaneous transluminal coronary revascularization.
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(12,13). The results of the present study suggest that this
strategy should be applied to eptifibatide as well.
Two other postprocedural variables that may have contrib-
uted to VAS complications include lower nadir platelet count
and the presence of a hematoma before sheath removal. Other
variables associated with VAS complications were more likely
a reflection of treatment of preexisting VAS complications.
These include prolonged bed rest, use of leg restraints, re-
moval of the sheath by a physician and use of a Femostop or
clamp (as mandated by the protocol). Because it was unclear
whether association of postprocedural variables with VAS
complications represented cause or effect, these postproce-
dural variables with significant univariate associations were not
included in the multivariable analysis.
Progress in preventing VAS complications of PTCR with
GP IIb/IIIa receptor inhibition. The first study of PTCR
during GP IIb/IIIa receptor inhibition was the EPIC trial,
which documented a 2.4% incidence of severe VAS bleeding in
placebo-group patients, with a threefold increase (7.6%) in
abciximab-treated patients. The current study of PTCR during
GP IIb/IIIa receptor inhibition with eptifibatide documents a
step forward in the prevention of VAS bleeding, with a 0.5%
incidence of severe VAS bleeding in placebo-treated patients
and only a 0.6% incidence in eptifibatide-treated patients.
Data from the EPILOG trial (23) demonstrate similar success
in minimizing VAS complications during PTCR with abcix-
imab, with a 0.7% incidence of severe VAS bleeding in
placebo-treated patients and a 0.7% incidence in abciximab/
low dose heparin-treated patients. The evolution of peripro-
cedural care during these three studies may account for the
improvement in VAS bleeding. First, heparin dosing protocols
were reduced (10,000 to 12,000 U of heparin in the EPIC trial,
100 U/kg in the IMPACT II trial and 70 U/kg in the low
heparin dose arm of the EPILOG trial). The ACT targets also
decreased from 300 to 350 s in the EPIC and IMPACT II trials
to .200 s in the EPILOG trial. Finally, discontinuation of
heparin after the procedure with early removal of sheaths
became more frequent during these three studies, occurring
rarely in the EPIC trial, more commonly (35% of patients) in
the IMPACT II trial and routinely in the EPILOG trial. These
changes in intensity of anticoagulation and postprocedural
VAS management are likely to have contributed to the dra-
matic reduction in VAS complications in placebo-treated
patients in the IMPACT II and EPILOG trials and the
dramatic reduction in excess VAS bleeding associated with GP
IIb/IIIa inhibition from threefold in the EPIC trial to negligible
in the IMPACT II and EPILOG trials.
Study limitations. The IMPACT II trial was not designed
primarily to determine predictors of access site complications.
However, the data used in the present analysis were collected
prospectively on case report forms designed to carefully assess
the incidence and significance of VAS complications. The
analyses reported here were anticipated in the IMPACT II
study design. Data were not collected prospectively for all VAS
problems, such as large hematomas requiring a prolonged
hospital stay or arteriovenous fistulas treated conservatively
but eventually needing surgical repair. Statistical analyses were
performed with the high and low dose eptifibatide groups
pooled. Although this might obscure some differences between
these groups, the incidence of any groin complication was not
significantly different (10.9% vs. 8.9%, p 5 0.08) between the
two groups. More frequent use of hemostasis clamps might
have decreased the incidence of VAS complications in the
present study.
The analyses used in the present study identify associations
between VAS complications and patient, procedural and post-
procedural variables. However, except for the study variable of
eptifibatide treatment, which was randomized, association
does not prove causality. Some of the variables associated with
VAS complications in this study may not be independent
predictors; rather, they may be dependent sequelae of the
complications or markers for other predictors.
Conclusions. Several factors under the control of the in-
terventionist are associated with VAS complications, including
PTCR within 24 h of thrombolytic therapy, use of venous
sheaths, stent placement (in the era of intense post-stent
anticoagulation), higher doses of heparin during the procedure
and later sheath removal. Although the present study does not
prove that manipulation of these factors can reduce VAS
complications, it would seem prudent to avoid the use of
venous sheaths when possible, avoid excessive heparin dosing
(aim for an ACT ;300 s) and remove sheaths as soon as
possible after the procedure. The wide variation in the inci-
dence of VAS complications among participating sites (25th
percentile 0%, 75th percentile 10%) suggests that optimal
VAS management practices may minimize VAS complications.
Further research is needed to identify optimal management
practices.
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